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6/j.bAge-related differences in thymic function influence the rapidity of T cell reconstitution following hemato-
poietic stem cell transplantation (HSCT). In adults, thymic reconstitution is delayed until after marrow en-
graftment is established, and is significantly improved by approaches that increase marrow chimerism,
such as pretransplantation irradiation. In contrast, we show that neonatal mice undergo more rapid and ef-
ficient thymic reconstitution than adults, even when bone marrow (BM) engraftment is minimal and in the
absence of pretransplantation radiation. We have previously shown that the neonatal thymus produces
high levels of vascular endothelial growth factor (VEGF) that drives angiogenesis locally. In this report, we
show that inhibition of VEGF prior to HSCT prevents rapid thymic reconstitution in neonates, but has no
effect on thymic reconstitution in adults. These data suggest that the early radiation-independent thymic re-
constitution unique to the neonatal host is mediated through VEGF, and reveals a novel pathway that might be
targeted to improve immune reconstitution post-HSCT.
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Immune reconstitution following allogeneic he-
matopoietic stem cell transplantation (HSCT) is
frequently slow and imperfect, with consequent
morbidity from opportunistic infections [1-5]. Several
factors contribute to immune dysfunction after
allogeneic HSCT, including the presence of graft-
versus-host disease, immune suppressive medications,
anddamage to the thymicmicroenvironment fromcon-
ditioning regimens and age-related involution [1-3].
Mature tolerant T cells are generated after HSCT
through a complex stepwise process that begins with
homing and engraftment in the marrow. Pretransplan-partment of Pathology and Laboratory Medicine,
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engraftment and proliferation in the marrow, with
subsequent differentiation into progeny that are re-
cruited to the thymus to generate donor-derived thy-
mocytes [3]. In murine studies, more than 2 weeks
are required for donor-derived CD41CD81 cells to
first appear in the thymus after transplantation [6]. In
the clinical setting, severe T lymphopenia persists in
patients for at least 100 days posttransplantation [1-5].
The paradigm that assumes robust thymic
reconstitution requires pretransplantation condition-
ing is challenged by observations made over several
decades in the setting of HSCT for Severe Combined
Immune Deficiency (SCID). When newborns and
young infants with SCID undergo HSCT from
HLA-matched siblings, T cell reconstitution can often
be accomplished without pretransplantation condi-
tioning [7-10]. In addition, T cell reconstitution
occurs rapidly and is more robust when HSCT for
SCID is performed in the newborn period [3,11,12],
suggesting that neonatal thymus is particularly
permissive to reconstitution with donor cells.
Postnatal thymic growth in immune-competent
humans and mice is most rapid during the neonatal
period [13-15]. Our group has shown that during
the first few days of murine postnatal life, the
thymus is a site of vigorous thymocyte proliferation
and vascular endothelial growth factor (VEGF)-
dependent angiogenesis [13]. Under the influence of lo-
cally produced VEGF, neonatal thymic vasculature is683
684 Biol Blood Marrow Transplant 18:683-689, 2012A. R. Cuddihy et al.a dense network of capillaries. Beyond the first week of
life, as VEGF dependence is lost, the capillaries meta-
morphose to a mature hierarchic adult vasculature.
Blocking VEGF during the neonatal period not only
causes loss of vascular density and capillary pruning,
but also reduces thymocyte numbers [13]. In the current
studies, we show that the unique pattern of thymic re-
constitution after bone marrow transplantation (BMT)
in the neonate is likely influenced by the same VEGF-
mediated mechanisms that contribute to robust thymo-
poiesis during normal neonatal development.MATERIALS AND METHODS
BMTand VEGF Inhibition
In all experiments, unfractionated bone marrow
(BM; 1  107 cells/animal) from 6- to 8-week-old
C57Bl6/J (CD45.2) mice was transplanted intrave-
nously into neonatal (1 day old, via facial vein) or adult
(6 weeks old, via retro-orbital injection) Non-Obese
Diabetic (NOD)/SCID/IL-2Rg2/2 (NSG; CD45.1)
mice (Jackson Research Laboratories, Bar Habor,
ME). Where indicated, mice were sublethally irradi-
ated 2 hours pre-BMT with 150 cGy (neonates) or
270 cGy (adults) using a Cs-137 source [13]. For the
timed transplant experiments in 1-, 4-, 7-, and 10-
day-old NSG mice, 1  107 unfractionated C57Bl6/J
BM (CD45.2) cells were injected intra-hepatically
without pretransplantation irradiation. In all indicated
experiments, neonates and adults received either
VEGF-Trap or hFc control (25 mg/kg) (Regeneron
Pharmaceuticals, Tarrytown, NY) [16] 24 hours prior
to BMT (and 22 hours prior to irradiation). Mice were
kept in specific pathogen-free facilities at Children’s
Hospital Los Angeles and University of California
Los Angeles under approved protocols.
In Vivo Labeling of Thymic Vasculature
Micewere anesthetized andperfusedwith amixture
of biotinylated tomato lectin (10 mg/kg; Vector Labo-
ratories, Burlingame, CA) and streptavidin-Cy3 (3.1
mg/kg; Jackson ImmunoResearch, West Grove, PA)
via facial vein (neonates) or cardiac injection (adults).
Two minutes later, mice were perfused with PBS fol-
lowed by 4% paraformaldehyde. Isolated thymi were
fixed in 4% paraformaldehyde [13]. Sections (200 mm
each) of 3% agarose-embedded thymi were examined
for lectin labeling using a Leica TCS SP1 confocal mi-
croscopewith a PlanApo 10/0.4NAobjectiveTokyo,
Japan and images acquired using Leica LCS software.
Where indicated, mice received either 25 mg/kg hFc
or VEGF trap intraperitoneally 24 hours before the
lectin staining. Due to the difficulty in identifying and
dissecting thymi from nontransplanted adult NSG
mice, thymi from NOD SCID b2m2/2 were used to
study the vasculature of adult immune deficient mice.Analysis
Mice were euthanized 3 or 6 weeks posttransplan-
tation for analysis of engraftment. Single cell suspen-
sions were created from thymi and BM of all
animals. The cells were incubated with Mouse BD
Fc Block (BD Biosciences, San Jose, CA) followed by
incubation with rat anti-mouse CD45.2 (FITC) to
identify donor cells and rat anti-mouse CD4 (APC)
and CD8 (PE) antibodies (all BD Biosciences). Cells
were acquired on a FACSCalibur or LSRII (BD Bio-
sciences), and data were analyzed using FlowJo soft-
ware (Tree Star, Ashland, OR). For morphological
analyses, 5-mm sections of paraffin-embedded thymi
were stained with hematoxylin and eosin H&E and ex-
amined using an Olympus BX51 microscope fitted
with a 4/0.13 phl objective Tokyo, Japan. Images
were acquired with an Olympus DP 72 digital color
camera (Tokyo, Japan) and DP2-BSW software.
Statistical Analysis
Data were analyzed using the Wilcoxon rank sum
test or mixed model analysis of variance to account
for inter-experiment variability. P values \.05 were
considered significant. All statistical analyses were per-
formed with statistical software SAS version 9.1 [17].RESULTS
NeonatalMurineThymus IsUniquely Permissive
to Rapid and Robust Reconstitution after BMT,
Independent of PretransplantationConditioning
To examine if the impact of radiation on thymic
and BM reconstitution is affected by recipient age,
immune-deficient neonatal and adult mice underwent
allogeneic BMT with or without prior conditioning
with sublethal doses of total body irradiation. Six weeks
after transplantation, donor chimerism in the BM was
significantly higher in all irradiated compared with
nonirradiatedmice, regardless of age at transplantation
(Figure 1A; P\ .001). Thus, pretransplantation irradi-
ation, even at sublethal doses, is required for efficient
BM engraftment irrespective of the host age.
Despite similar patterns of BM chimerism in both
age groups, a profound difference was seen in the pat-
tern of thymic reconstitution between neonatal and
adult recipients. In parallel with BM chimerism,
reconstitution of the thymus in adults was almost un-
detectable in nonirradiated recipients, and was signifi-
cantly increased with irradiation (Figure 1B; P\ .001).
Thymic reconstitution was significantly greater in
mice that received transplantations as neonates when
compared with adult recipients, irrespective of irradia-
tion (Figure 1B; P\ .01 for irradiated and P\ .001 for
nonirradiated cohorts). In addition, thymic reconstitu-
tion in neonates was rapid; even in the absence of irra-
diation, donor cells were detected in the thymus as
Figure 1. Neonatal mice show rapid and robust thymic reconstitution after HSCT. (A) Frequency of CD45.21 donor cells in the bone marrow of
nonirradiated (2, black bars) or irradiated (1, grey bars) neonates or adult NSG mice analyzed 6 weeks posttransplantation (neonates: no radiation
therapy [XRT] n5 22 versus XRT n5 16; adults: no XRT n5 13 versus XRT n5 18). All numbers are mean6 SEM. (B) Thymocyte numbers, 6 weeks
posttransplantation (neonates: no XRT n5 13 versus XRT n5 14; adults: no XRT n5 9 versus XRT n5 8). (C) Fluorescent activated cell sorter (FACS)
plot comparing thymic and bone marrow reconstitution with donor (CD45.21) cells at 1 and 2 weeks posttransplantation in NSG neonates. (D) FACS
plots showing de novo generation of double positive (CD41CD81) thymocytes 2 weeks posttransplantation in nonirradiated neonatal NSGmice (right
panel); isotype control for CD4 and CD8 (left panel). *P\.01, **P\.001.
Biol Blood Marrow Transplant 18:683-689, 2012 685Neonatal Thymic Reconstitution and VEGFearly as 48 hours (data not shown) and efficiently
reconstituted the thymus at 1 and 2 weeks posttrans-
plantation when compared with BM reconstitution
(Figure 1C). By 2 weeks, most donor thymocytes had
progressed to the double positive (DP; CD41CD81)
stage (Figure 1D).Thymic Vasculature in Immune-Deficient and
Immune-Competent Mice Is VEGF-Dependent
during the Neonatal Period
We have previously reported that the thymic vas-
culature in immune-competent neonatal mice
Figure 2. Immature vascular architecture and robust thymic reconstitution are lost during the first week of postnatal life. (A) In vivo tomato lectin
staining comparing vasculature between newborn (left panel) and adult (right panel) immune-competent (C57Bl/6) and immune-deficient (NOD/
SCID/b2m–/–) mice. (B) Vascular endothelial growth factor (VEGF)-Trap reduces vascular density of newborn thymi in immune-competent (C57Bl/
6) and immune-deficient (NSG) mice. Control mice were treated with hFc. (C, D) Effect of host age on bone marrow (C) and thymic reconstitution
(D). NSG neonatal mice were transplanted with CD45.21 bone marrow (BM) without irradiation at day 1, 4, 7, and 10 of life, (n 5 4, 7, 7, and 9
mice, respectively) and analyzed at 3 weeks post–bone marrow transplantation (BMT). All numbers are mean 6 SEM.
686 Biol Blood Marrow Transplant 18:683-689, 2012A. R. Cuddihy et al.consists of a dense capillary network that is VEGF-
dependent [13]. By adulthood, the vasculature has
matured to a hierarchic pattern losing most of the
capillaries and becoming VEGF-independent [13].
Although largely devoid of thymocytes, thymi of
immune-deficient neonatal mice have the same dense
capillary network as immune-competent neonatal
mice, and this vascular phenotype is similarly lost
by adulthood (Figure 2A). As with immune-
competent mice, inhibition of VEGF in the
immune-deficient neonatal thymus causes loss of
dense capillaries and the appearance of an adult vas-
cular pattern (Figure 2B).TheWindow of Efficient, Radiation-Independent
Thymic Reconstitution Closes during the First
Week of Postnatal Life
Our previous work showed that VEGF-dependent
vasculature of the thymus transitions to a mature
VEGF-independent vasculature during the first week
of life (ie, by the end of the murine neonatal period)
[13].We therefore evaluated if the permissive environ-
ment for thymic reconstitution post-HSCT also
changes during the first week of life. Animals were
transplanted without prior irradiation at 1, 4, 7, or
10 days after birth, and thymocyte numbers were ana-
lyzed 3 weeks after transplantation. Age at time of
Biol Blood Marrow Transplant 18:683-689, 2012 687Neonatal Thymic Reconstitution and VEGFtransplantation did not affect the level of donor chime-
rism in the bone marrow (Figure 2C). However, the
ability of donor cells to reconstitute the thymus
declined markedly during the first week of life
(Figure 2D), a pattern coinciding with the previously
reported temporal changes in vascular density and
VEGF-dependence [13].
VEGF Inhibition Significantly Delays Thymic
Reconstitution in Neonatal NSG Mice
In view of the parallel decline in thymic reconstitu-
tion and VEGF-dependence of thymic vasculature, we
administered VEGF-Trap (a VEGFR1/2 fusion recep-
tor [18]) 24 hours before transplantation to determine if
thymic reconstitution was VEGF-dependent. VEGF
inhibition significantly delayed thymic reconstitution
innonirradiated neonatalmice, as shownby a significant
reduction in donor thymopoiesis at 3 weeks post-BMT
(Figure 3A; P\ .01). A similar trend was seen 3 weeks
after transplantation of irradiated neonatal mice
(Figure 3B). By 6 weeks posttransplantation, thymocyte
numbers had increased to equivalent levels in control
and VEGF-Trap-treated neonates (Figure 3A and B),
demonstrating that VEGF inhibition did not limit the
ability of the thymus to recruit and support proliferation
of precursors through the more typical mechanisms of
reconstitution that occur after marrow engraftment is
well-established. In contrast, thymic reconstitution of
irradiated adults was not affected by pretransplantation
VEGF inhibition (Figure 3C).
The age-specific effect of VEGF inhibition was
also seen when examining the differentiation stages of
donor-derived thymocytes. Treatment with VEGF-
Trap resulted in a higher frequency of the immature
CD42CD82 double negative (DN) fraction in both
nonirradiated (Figure 3D) and irradiated newborn
mice (Figure 3E; P\ .01) at 3 weeks post-BMT. The
frequency of CD41CD81 DP thymocytes corre-
spondingly dropped with VEGF inhibition in nonirra-
diated (Figure 3G) and irradiated (Figure 3H; P\ .01)
neonatal mice. However, by 6 weeks, VEGF inhibition
had no effect on the frequencies of DN or DP thymo-
cytes in the newbornmice (Figure 3D-H). VEGF inhi-
bition had no effect on the frequency ofDP orDNcells
in adults (Figure 3F and I). Thus, VEGF inhibition in
the neonate resulted in both lower numbers of total
thymocytes and a more immature thymocyte profile
at 3 weeks post-BMT, consistent with a delay in thymic
reconstitution. The frequencies of single positive
CD41 and CD81 cells in both newborn and adult
mice were not affected by VEGF inhibition (data not
shown), suggesting that VEGF is unlikely to be in-
volved in the egress of mature thymocytes.
The effects of VEGF inhibition on thymic recon-
stitution were confirmed by analysis of thymic size and
histology. Three weeks posttransplantation, thymi
from VEGF-Trap-treated neonates were smaller andlacked the medullary and cortical structures of control
mice, regardless of whether the mice were irradiated
before transplantation. By 6 weeks, thymi from
VEGF-Trap-treated mice showed similar thymic ar-
chitecture and size compared with control mice, again
demonstrating that VEGF inhibition did not perma-
nently damage the thymus architecture or function
(Figure 3J, K).
The size and histology of the thymi from irradiated
adult NSG mice was not affected by VEGF inhibition
(Figure 3L). Of note, at three weeks post-BMT, thymi
from mice transplanted as adults were significantly
smaller and less cellular than those transplanted as ne-
onates, inmost cases being too small to clearly identify.
By six weeks post-BMT, even though thymi from adult
recipients had developed distinct cortical and medul-
lary structures (Figure 3L), they never achieved sizes
equivalent to those frommice transplanted as neonates.DISCUSSION
Our data demonstrate that the thymus of the new-
born immune-deficient mouse provides a highly per-
missive environment for rapid thymic reconstitution
after BMT, and that VEGF-mediated mechanisms
have a role in producing this unique environment.
The thymicmicroenvironment changes during the first
7 days after birth, during which time the thymic vascu-
lature matures and becomes VEGF-independent [13].
Neonatal thymic reconstitution is both rapid and
robust, does not require pretransplantation condition-
ing, and does not require a high level of BM chimerism.
During steady state, ingress of progenitors into the
thymus occurs in waves in response to the availability
of empty intra-thymic niches [19-21]. These waves of
recruitment and ‘‘settling’’ of marrow-derived progeni-
tors in the adult murine thymus are thought to be medi-
ated at least partly by interactions between the homing
molecules P-selectin with PSGL-1 [22], and the chemo-
kine receptors CCR7 and CCR9 with their ligands
[23,24]. Zlotoff et al. [25] found that although long-
term thymic reconstitution after BMT used the same
mechanisms as seen in steady state, early (3 weeks post-
BMT) thymic reconstitution occurred independently
of CCR7 and CCR9 [25]. It is interesting to note that
in our own study with neonatal animals, dependence
on VEGF was also different between the 3-week and 6-
week phases of reconstitution, irrespective of irradiation.
Although the data from Zlotoff et al. [25] was generated
in a different transplantation setting fromour own (adult
irradiatedmice versus neonatal mice), the 2 studies share
the concept that early and late thymic reconstitutionmay
be mediated by different mechanisms.
We propose that high local VEGF specifically
affects the early phase of thymic seeding in neonates,
as VEGF inhibition reduces thymocyte numbers 3
weeks after BMT. By 6 weeks after BMT, when the
Figure 3. Vascular endothelial growth factor (VEGF) inhibition impairs early thymic engraftment of donor cells in mice transplanted as neonates, but
not adults. (A) Number of thymocytes in nonirradiated neonates harvested at 3 weeks (hFc [black bars] n5 9; VEGF-Trap [grey bars] n5 11; *P\.01)
and 6 weeks (hFc n5 14; VEGF-Trap n5 11; P 5 .30). (B) Number of thymocytes in irradiated neonates harvested at 3 weeks (hFc n5 6; VEGF-Trap
n5 5; P5.14) and 6 weeks (hFc n5 5; VEGF-Trap n5 4; P5.5). (C) Number of thymocytes in irradiated adults harvested at 3 weeks (hFc n5 8; VEGF-
Trap n 5 6; P 5 .48) or 6 weeks (hFc n 5 7; VEGF-Trap n 5 6; P 5 .84). P values were unchanged when thymocyte numbers were normalized to body
weight, to account for the smaller size of the VEGF-Trap treatedmice. (D-I) Percentage of CD42CD82; double-negative (DN) (D-F) andCD41CD81;
double-positive (DP) (G-I) thymocytes from mice treated with hFc (black bars) and VEGF-Trap (grey bars) before transplantation. (D, G) Nonirradiated
neonates harvested 3 weeks (hFc n5 9; VEGF-Trap n5 5) and 6 weeks (hFc n5 8; VEGF-Trap n5 6) posttransplantation. (E, H) Irradiated neonates
harvested 3 weeks (hFc n5 5; VEGF-Trap n5 3, *P\.01) and 6 weeks (hFc n5 5; VEGF-Trap n5 4) posttransplantation. (F, I), Irradiated adults har-
vested 3 weeks (hFc n5 4; VEGF-Trap n5 2) and 6 weeks (hFc n5 6; VEGF-Trap n5 6) posttransplantation. (J-L) H&E stains of thymi from NSGmice
treated as described in (A-C) harvested at 3 and 6 weeks. All images shown are at original magnification4. (J) Nonirradiated NSGmice transplanted as
neonates. (K) Irradiated NSG mice transplanted as neonates. (L) Irradiated NSG mice transplanted as adults. In (L), the largest examples of tissue from
the 3-week adult cohorts are shown because, in most cases, the thymus was not detected.
688 Biol Blood Marrow Transplant 18:683-689, 2012A. R. Cuddihy et al.delivery of thymic precursors is dependent on previ-
ously described mechanisms of recruitment from the
BM, the effect of VEGF inhibition on thymocyte
numbers is not evident. This later production of
marrow-derived thymocytes presumably overlaps and
further adds to the thymopoiesis derived from the ini-
tial phase of thymic seeding, thereby accounting for
higher levels of thymocyte production in neonates
even at later time points.
Porritt et al. [6] found that at least 13 days (average
.15 days) were required for cells entering the adult
thymus to reach the outer cortex and begin to differen-tiate intoDP cells, and even by 3 weeks after transplan-
tation, most donor cells had not passed the DN3 stage
of differentiation. In our own studies,.95% of donor
cells had reached the DP stage of thymocyte differen-
tiation by 2 weeks after transplantation of neonatal an-
imals. VEGF inhibition in the newborn mice skewed
the thymocyte differentiation toward a more immature
phenotype with a higher frequency of DN and rela-
tively fewer DP thymocytes.We postulate that in new-
born mice, VEGF-dependent vasculature permits
rapid ingress of thymic progenitors (possibly even by
direct seeding before marrow engraftment), which
Biol Blood Marrow Transplant 18:683-689, 2012 689Neonatal Thymic Reconstitution and VEGFthen undergo proliferation in an empty niche resulting
in rapid and robust reconstitution of the thymus. It is
also possible that local VEGFmediates rapid reconsti-
tution of the thymus by augmenting differentiation of
DN to DP thymocytes, and subsequent proliferation
through mechanisms that are yet to be elucidated.
It is intriguing to speculate whether the processes
described here in the murine setting may also contrib-
ute to the robust thymopoiesis seen in clinical trans-
plantations of infants, particularly in those with
SCID who, without pretransplantation conditioning,
can achieve rapid T cell reconstitution with little or
no donor contribution to the myeloid and B cell
lineages [26,27]. Our findings reveal previously
unreported mechanisms that mediate efficient thymic
reconstitution in neonates, and present novel
pathways that might be targeted to improve post-
BMT immune reconstitution in the adult.
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